• Ari Moskowitz, Lars W Andersen, David T Huang, Katherine M Berg, Anne V Grossestreuer, Paul E Marik, Robert L Sherwin, Peter C Hou, Lance B Becker, Michael N Cocchi, Pratik Doshi, Jonathan Gong, Ayan Sen, and Michael W Donnino.
• Beth Israel Deaconess Medical Center, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Boston, MA, USA.
• Crit Care. 2018 Oct 29; 22 (1): 283283.

AbstractThe combination of thiamine, ascorbic acid, and hydrocortisone has recently emerged as a potential adjunctive therapy to antibiotics, infectious source control, and supportive care for patients with sepsis and septic shock. In the present manuscript, we provide a comprehensive review of the pathophysiologic basis and supporting research for each element of the thiamine, ascorbic acid, and hydrocortisone drug combination in sepsis. In addition, we describe potential areas of synergy between these therapies and discuss the strengths/weaknesses of the two studies to date which have evaluated the drug combination in patients with severe infection. Finally, we describe the current state of current clinical practice as it relates to the thiamine, ascorbic acid, and hydrocortisone combination and present an overview of the randomized, placebo-controlled, multi-center Ascorbic acid, Corticosteroids, and Thiamine in Sepsis (ACTS) trial and other planned/ongoing randomized clinical trials.

26 keywords...

hide…